US Patent

US9713642 — Itraconazole compositions and dosage forms, and methods of using the same

Method of Use · Assigned to Mayne Pharma International Pty Ltd · Expires 2033-06-21 · 7y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical compositions containing itraconazole, including solid oral dosage forms, and methods of using them to treat fungal infections.

USPTO Abstract

The disclosure relates to, among other things, pharmaceutical compositions, such as solid oral dosage forms, comprising itraconazole, methods of making the compositions, and methods of using the same for treating disorders including, but not limited to, fungal infections.

Drugs covered by this patent

Sporanox (itraconazole) · Sebela Ireland Ltd

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2453`	—	Sporanox

Patent Metadata

Patent number: US9713642
Jurisdiction: US
Classification: Method of Use
Expires: 2033-06-21
Drug substance claim: No
Drug product claim: No
Assignee: Mayne Pharma International Pty Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.